Antiviral Compositions and Methods of Use

Case ID:
C01614

Technical Details:

This invention is related to isolation of two highly potent, non-toxic inhibitors against human immunodeficiency virus type 1 (HIV-1) integrase and viral replication. Two water soluble compounds, M522 and M532, have been discovered by isolating them from Salvia miltiorrhiza roots in purities of > 99.5 % as reported by NMR spectral analysis. These two compounds are potent anti-HIV inhibitors and showed no cytotoxicity to human H9 cells at high concentrations. Both M522 and M532 inhibited HIV-1 integrase and acute infection of HIV-1 replication of different strains in drug-resistant and primary isolates with very low doses in human H9 cells. These two drugs are selective integrase inhibitors and hold promise as a novel class of therapeutic drugs for AIDS patients based on their high potencies and absence of cytotoxicity

 

Looking for Partners:

The discovered drugs are potent and non-toxic integrase inhibitors and they can be used for treatment of AIDS patients in the future.

 

Patent Status: US patent granted US 7,071,227

 

Publications: Antiviral Res. 2002 Jul;55(1):91-106.


Patent Information:
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum